Progress in the understanding of cancer biology have driven the development of drugs against specific molecular targets, such as epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). This evidence concerns the gene VEGFA and cancer.